Savara (SVRA) Current Deferred Revenue (2018 - 2020)

Savara (SVRA) reported Current Deferred Revenue of $243000.0 for Q2 2020, up 2.1% on a QoQ basis from $238000.0 in Q1 2020.

Savara (SVRA) has 3 years of Current Deferred Revenue data on file, last reported at $243000.0 in Q2 2020.

  • Quarterly Current Deferred Revenue changed N/A year-over-year to $243000.0 in Q2 2020, while the trailing twelve-month figure through Jun 2020 was $243000.0 (changed N/A YoY) and the FY2018 annual result came in at $250000.0, changed N/A from the prior year.
  • Current Deferred Revenue improved to $243000.0 in Q2 2020 per SVRA's latest filing, from $238000.0 in the prior quarter.
  • Across five years, Current Deferred Revenue topped out at $250000.0 in Q4 2018 and bottomed at $238000.0 in Q1 2020.
  • The 3-year median for Current Deferred Revenue is $242500.0 (2019), against an average of $243250.0.
  • Peak annual rise in Current Deferred Revenue reached 1.65% in 2020, while the deepest fall reached 1.65% in 2020.
  • Tracing SVRA's Current Deferred Revenue over 3 years: stood at $250000.0 in 2018, then retreated by 3.2% to $242000.0 in 2019, then climbed by 0.41% to $243000.0 in 2020.
  • Per Business Quant, the three latest SVRA Current Deferred Revenue figures stand at $243000.0 (Q2 2020), $238000.0 (Q1 2020), and $242000.0 (Q1 2019).

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Quantum Biopharma 961,148.99 Bn 961,148.98 Bn -
2 Alterity Therapeutics 744,933.29 Bn 744,933.26 Bn -
3 Legend Biotech 2,540.00 Bn 2,539.71 Bn 242.10 Mn
4 Nanobiotix 2,199.85 Bn 2,199.78 Bn -
5 Akari Therapeutics 1,635.88 Bn 1,635.88 Bn -
6 Vertex Pharmaceuticals 111.32 Bn 104.07 Bn 2.59 Bn
7 Evaxion A 62.56 Bn 62.54 Bn -
8 Regeneron Pharmaceuticals 62.55 Bn 53.79 Bn 3.31 Bn
9 Alnylam Pharmaceuticals 39.57 Bn 36.56 Bn 959.66 Mn
10 Savara 1.30 Bn 1.30 Bn -

Historic Data

Download Data 🔒
DateValue
Jun 30, 2020 243,000.00
Mar 31, 2020 238,000.00
Mar 31, 2019 242,000.00
Dec 31, 2018 250,000.00